ONWARD Medical to Release Q2 2026 Financial Results in Webcast

ONWARD Medical, a leading neurotechnology company, will release its first-half 2026 financial results and provide a comprehensive business update in a webcast scheduled for September 9, 2026. The event, led by CEO Dave Marver, will begin at 2:00 p.m. Central European Summer Time (CEST) or 8:00 a.m. Eastern Daylight Time (EDT). To participate, interested parties must register via the provided link, with recordings and supporting materials available afterward at the company’s investor relations website, ir.onwd.com.

Based in the Netherlands, ONWARD Medical has established a presence in Switzerland and the United States, with headquarters in Boston, Massachusetts. The company is dedicated to developing therapies aimed at restoring movement, function, and independence for individuals with spinal cord injuries and other movement disabilities. Its flagship product, the ARC-EX® System, has received clearance for commercial sale in the United States and Europe, and it is also advancing an investigational implantable system, ARC-IM®, which includes a brain-computer interface and artificial intelligence technology.

The webcast will offer a detailed overview of ONWARD Medical’s recent achievements and future plans. The company has received 10 Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA) for its ARC Therapy, highlighting its innovative and cutting-edge approach. ARC-IM® is designed to address unmet medical needs, such as blood pressure instability following spinal cord injury, and could potentially revolutionize the treatment of spinal cord injuries by integrating with brain-computer interfaces.

Sébastien Cros, Vice President of Communications at ONWARD Medical, noted, "This webcast will provide a comprehensive update on our progress and future direction. We are excited to share the latest advancements in our therapies and to engage with our stakeholders."

The company also cautions that forward-looking statements in the press release may not materialize due to various risks and uncertainties. Investors are advised to consider these factors carefully.

ONWARD Medical’s commitment to advancing neurotechnology remains steadfast, with the company poised to continue its pioneering work in restoring movement and independence for individuals with spinal cord injuries and other disabilities.